US EditionPCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
- Purchasers of Pacira BioSciences, Inc. Securities between August 2, 2023, and August 8, 2024, have a deadline of March 14, 2025, to apply as lead plaintiffs in a class action lawsuit.
- The lawsuit claims that statements made by Pacira during the class period were false and misleading regarding patent protections for Exparel.
- Pacira's claims about the strength of its patent protections were not as solid as publicly stated, leading to alleged damages for investors.
- Investors who purchased Pacira securities during the class period may be eligible for compensation without any costs through a contingency fee arrangement.
Insights by Ground AI
Does this summary seem wrong?
33 Articles
33 Articles
All
Left
1
Center
6
Right
1
Coverage Details
Total News Sources33
Leaning Left1Leaning Right1Center6Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
13%
C 75%
13%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
